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Abstract
Purpose: The purpose of this investigation was to evaluate the effects of combined (estradiol
and progestin) monophasic oral contraceptive pill (OCP) use on thermoregulation. Further, we
sought to evaluate OCP use on acute rehydration post-exercise in the heat using recommended
rehydration guidelines. Methods: Eleven healthy, aerobically trained (VO2peak = 47.8 ± 4.7
mL/kg/min), long term female oral contraceptive users completed a familiarization trial and two
experimental days separated by ≥ 7 days. The two experimental trials were identical except for
the hormone dosing phase. One trial was completed during the third week of active pill dosing
(ACT) and one during the placebo week (PLA) of their normally prescribed OCPs. Participants
completed 90 minutes of cycling in 30ºC and 55% relative humidity and a rehydration protocol.
Exercise intensity was set at 55% of the wattage attained during the final stage of the VO2peak
test. Trec, heart rate, blood pressure and perceptual measurements were recorded every 15minutes. Body mass change was measured continuously and recorded every 15-minutes and
subsequently used to provide water (warmed to 38°C) to replace sweat losses. Water was given
to the participant to match 50% of sweat loss at each time point. Metabolic data (VO2) wattage
and cadence was collected at 30-minutes, 60-minutes, 75-minutes and at the cessation of
exercise (Hashimoto et al., 2016) to ensure work intensity was kept constant. 125% of fluid lost
was replaced via a recovery beverage and water post-exercise. Results: Tre demonstrated a
significant main effect difference for ACT to be greater than PLA compared to PLA (F1.55,15.53 =
74.019, P < 0.001). There was also a significant main effect for Tre to increase over time,
regardless of trial (F1,10 = 24.064, P < 0.001). There was not an interaction of time x trial
(F1.96,19.62 = 1.822, P = 0.189) for Tre. There was no difference in overall change in temperature
(baseline to maximum temperature) between trials (ACT: 1.3 ± 0.5ºC, PLA: 1.4 ± 0.4ºC, t10 = -

0.588, P = 0.570). Post-exercise, there was no difference between trials in the amount of fluid
consumed (ACT: 1007 ± 256 mL; PLA: 921 ± 448 mL, t10 = 0.874, P = 0.403). There was no
difference in spot sample USG assessed 3-h post-trial between trials (t7 = -0.743, P = 0.487).
Likewise, 3-h spot sample urine osmolality was not different between trials (t7 = - 1.177, P =
0.287). Urgency to void at 3-h post-trial was not different between groups (t7 = - 1.000, P =
0.351). Perception of thirst was not different 3-h post-trial (t7 = - 0.3859, P = 0.711).
Conclusion: We demonstrated a significant difference in core temperature elevation during the
ACT trial. However, in following recommended hydration guidelines, OCP phase has no effect
on fluid retention post-exercise in the heat.
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I. Introduction
As women continue to participate more in sport, contribute to the workforce, and enlist as
military personnel, there is an increased need for specific safety guidelines and hydration and
nutrition recommendations (Giersch et al., 2019; Sims & Heather, 2018). To outline proper
recommendations, understanding female specific physiology should be prioritized. Often, heat
and hydration research is conducted on men. Most of the existing literature attributes differences
in physiology to body size discrepancies mainly due to total body surface area and body
composition variability between sexes. While these physical differences do exist, research in this
area has ignored the potential influences of the female menstrual cycle. Unfortunately, this
assumption underserves half of the human population.
The impact of female hormones on fluid regulation is not fully understood. While it is
known that female reproductive hormones impact volume regulatory physiology (Stachenfeld,
2008), the pursuit to fully understand the differences of hormonal fluctuations and fluid balance
throughout the menstrual cycle has been lackluster. It has become common practice to exclude
females in fluid balance research due to physiological fluctuations throughout the menstrual
cycle. There are differences due to the menstrual cycle but these differences are not fully
understood (Sims & Heather, 2018), and therefore, are not well-controlled in methodological
design. When female participants are included in hydration or fluid balance studies, it is common
to limit testing during the early follicular phase of the menstrual cycle. During this phase,
estrogen and progesterone are at their lowest concentrations (Constantini et al., 2005; Sims &
Heather, 2018; Stachenfeld, DiPietro, et al., 1999; Stachenfeld & Taylor, 2014). The logic is that
lower concentrations of circulating female hormones reveal outcomes similar to males without
considering the effect that hormonal fluctuations may have throughout the menstrual cycle.
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Exercising in the heat requires cardiovascular and thermoregulatory adjustments to
maintain both core body temperature and mean arterial pressure (González-Alonso et al., 2000;
Montain et al., 1995; Montain & Coyle, 1992; Sawka et al., 2001; Wendt et al., 2007). When
dehydration is combined with exercise in the heat, there is substantial impairment in stroke
volume due to total blood volume reductions (González-Alonso et al., 2000). Cardiac output
(CO) is reduced during dehydration compared to an euhydrated state (González-Alonso et al.,
1997). This reduction in CO results in a reduction in muscle blood flow, which leads to
sacrificed performance (Casa et al., 2010; González-Alonso et al., 1998). To prevent heat illness
and maintain performance, individual fluid recommendations have been proposed (McDermott et
al., 2017). Yet, little research has been collected in female participants.
It has been proposed that sex steroids affect thermoregulation by changing the regulated
hypothalamic temperature, or “set-point” (Stachenfeld et al., 2000). Animal studies have shown
that estrogen and progesterone act on sex steroid binding neurons in the preoptic, anterior
hypothalamus (Silva & Boulant, 1986). Progesterone is highest during the luteal phase of the
menstrual cycle and is associated with an increase in resting core body temperature of 0.3-0.8°C
(Baker et al., 2020; Charkoudian & Johnson, 1999; Charkoudian & Stachenfeld, 2016;
Constantini et al., 2005; Kolka & Stephenson, 1989; Pivarnik et al., 1992; Rogers & Baker,
1996). Physiological outcomes during the midluteal phase would therefore be attributed to an
influence of elevated sex hormones.
However, further complicating female physiology studies in dehydration and
thermoregulation is oral contraceptive (OC) use. According to the National Center for Health
Statistics data from the 2015-2017 National Survey of Family Growth, 64.9% of the 72.2 million
women aged 15-49 in the U.S. were using contraception (Daniels, 2015). Of the reversible
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methods of contraception, the most common was oral contraceptive pills (12.6%) within the
previously mentioned age range (Daniels, 2015). Stachenfeld et al. (2018) reported that >90% of
European and U.S. females are currently taking or previously have taken oral contraceptives. In
athletes, the prevalence of females taking combined, monophasic oral contraceptives is 50% (Lei
et al., 2019). Fluid balance studies suggest OCs containing estrogen (combined hormone OCs)
increase osmotically induced AVP and thirst during dehydration and ad libitum rehydration,
even though there were no changes in water retention (Stachenfeld, Silva, et al., 1999);
confirming the hypothesis that estrogen is responsible for decreasing the plasma osmotic
threshold. Thermoregulation studies suggest the rightward shift of the thermoregulatory set-point
is maintained with OC use, this finding is exacerbated with exercise in hot and humid
environments (Lei et al., 2019).
To date, there is insufficient data on the effects of OC use on fluid balance and
thermoregulatory outcomes. Females are likely to be at no more of a disadvantage during
exercise in the heat when compared to male counterparts (Charkoudian & Stachenfeld, 2016).
However, a better understanding of female physiology may lead to advantages in sport and work
performance, establish better criteria for determining heat intolerance, and potentially lead to
better safety guidelines as more females play sports, join the military or occupational workforce.
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Specific Aims
Aim 1. Identify the effect of monophasic oral contraceptive pill use on thermal physiology
variables (core temperature, skin temperature, total sweat loss and sweat rate).
Research Hypothesis 1. Exogenous levels of progesterone increase core body temperature in
eumenorrheic females. It is expected that participants may reach a higher core temperature
during active pill dosing compared to placebo pill dosing due to the thermoregulatory set-point
shift.
Aim 2. Identify the effects of monophasic oral contraceptive pill use on acute rehydration postexercise in the heat.
Research Hypothesis 2: Previous research in our lab suggests no difference in fluid retention or
turnover in oral contraceptive users between active pill dosing versus placebo pill dosing in
resting conditions. Because fluid loss via sweat will be replaced via water consumption during
exercise, it is expected there will not be significant differences between active and placebo pills
on OC users in fluid volume turnover post-exercise.
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II. Literature Review
Fluid Balance in Resting Conditions
In the human body, water constitutes 50-70% of total body weight (Sawka et al., 2005).
Variability in total body water (TBW) is due to differences in body composition as water
composes 65-75% of the weight of muscle and about 10% of fat (McArdle et al., 2015). Because
body fat has a low water content compared to muscle, individuals with greater body fat have a
decreased percentage of TBW compared to total body mass (McArdle et al., 2015). TBW is
distributed into two fluid compartments: intracellular and extracellular. The intracellular fluid
compartment is larger and contains about 62%-65% of TBW, whereas the extracellular
compartment is made up of interstitial and plasma spaces, containing 30%-35% of TBW. Blood
plasma accounts for nearly 20% of extracellular fluid (McArdle et al., 2015).
Approximately 5%-10% of TBW is replaced daily in the absence of exercise. This
turnover includes respiratory water loss, influenced by environmental conditions (temperature
and humidity), pulmonary ventilation, urine, and feces. Metabolic water is formed via oxidation
of substrates but is offset by respiratory water loss. (McArdle et al., 2015). Urine output per day
is approximately 1-2 L, and varies depending on food and fluid consumption (Armstrong et al.,
2010; McArdle et al., 2015) and may be less in females (Armstrong et al., 2012). Urine output is
the primary avenue to regulate net body water balance in resting conditions (McArdle et al.,
2015; Sawka et al., 2005)
Net body water balance (loss = gain) is maintained because of thirst and hunger drive and
ad libitum access to food and fluid to offset water loss. The ability to regulate TBW is due to an
interplay between neuroendocrine and renal responses to blood volume and tonicity changes.
Further socio-behavioral factors such as water seeking behavior or removal from thermal
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conditions add to TBW regulation. When fluids are inadequately consumed, water retention is
dependent on hormonal release (Sawka et al., 2005).
Arginine vasopressin (AVP), also known as antidiuretic hormone, is vital to fluid
balance. AVP is produced in the paraventricular nucleus (PVN) and supraoptic nucleus (SON) of
the hypothalamus and secreted by the posterior pituitary gland. AVP is released in response to
feedback from osmolality (osmoreceptors) and blood pressure changes (baroreceptors) in order
to maintain homeostasis (Bankir, 2013; Baylis & Robertson, 1980; Koshimizu et al., 2012;
Robertson, 1984; Robertson et al., 1976; Share, 1996). AVP release occurs at a plasma
osmolality of ~280 mOsm/kg (Robertson, 1984; Robertson et al., 1976) and for every 1%
increase in plasma osmolality a 1.8 pg/mL increase in AVP is induced (Baylis & Robertson,
1980).
When fluid losses are greater than gains, resulting in a hypohydrated state, plasma
osmolality increases and AVP is released. At a slightly higher plasma osmolality (~ 290-300
mOsm/l) (Baylis & Robertson, 1980; Thornton, 2010), osmoreceptors in the brain increase thirst
(Thornton, 2010). Magnocellular neurons in the hypothalamus (PVN and SON) then stimulate
the release of AVP (Thornton, 2010). Similarly, as blood volume decreases, the reduction in
blood pressure triggers baroreceptors that lead to AVP release. The action of AVP is widespread
and, in some cases, its actions are not clearly understood. However, one of the most important
actions is water conservation at the kidney. AVP acts on vasopressin receptor 2 (V2) in the renal
tubules and collecting duct, which stimulate the action of aquaporin channels to reabsorb water
into the vasculature, producing a concentrated urine (Johnson et al., 2016; Koshimizu et al.,
2012). The action of AVP on vasopressin receptor 1 alpha (V1a) located in the walls of the
vasculature also cause increases in blood pressure, subsequently increasing cardiovascular
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stability (Koshimizu et al., 2012). AVP has many other non-fluid regulatory actions such as
influencing pain perception, cognitive function, bone development and breakdown and the aging
process (Mavani et al., 2015), thus it has also been termed a survival hormone (Johnson et al.,
2016; Koshimizu et al., 2012).
Other hormones such as angiotensin and aldosterone are responsible for fluid balance and
act to concentrate urine and conserve fluid (Gellai et al., 1979). As renal perfusion decreases, the
juxtaglomerular apparatus detects these changes and releases renin. (Gellai et al., 1979). Renin
acts to convert angiotensinogen to angiotensin I, a biologically inert hormone (Sparks et al.,
2014). Angiotensin I is then converted to angiotensin II when angiotensin converting enzyme
(ACE) is abundant, which directly induces blood pressure increases through actions on smooth
muscle of the vasculature (Sparks et al., 2014). Angiotensin II stimulates the release of
aldosterone from the adrenal glomerulosa and thirst centers in the brain (Sparks et al., 2014;
Thornton, 2010). Aldosterone increases blood pressure through actions in the vasculature and
stimulates the reabsorption of Na+ and excretion of K+ from the kidney. This aids in fluid
preservation as the increased sodium retention allows for greater water movement into the
vasculature as a result of increased osmolality (Thornton, 2010). Concomitantly, the reninangiotensin-aldosterone system (RAAS) helps maintain fluid balance through thirst stimulation
to increase water seeking behaviors, which are essential to proper hydration (Thornton, 2010).
AVP, angiotensin I and II, and aldosterone are primary hormones needed to maintain fluid
balance. However, the interplay between these hormones and other circulating hormones must be
considered to fully conceptualized hormonal influence on fluid retention and excretion.
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Female Hormones and Fluid Balance
Why Sex Differences Matter
It has become standard practice to only test females during the early follicular phase of
the menstrual cycle when including them in hydration and fluid balance studies. During the early
follicular phase, estrogen and progesterone are at their lowest concentrations (Constantini et al.,
2005; Sims & Heather, 2018; Stachenfeld, DiPietro, et al., 1999; Stachenfeld & Taylor, 2014).
The theory is lower concentrations of circulating female hormones reveal outcomes similar to
males allowing for a homogenous sample size. However, resting plasma AVP is greater in males
than in females during the follicular phase of the menstrual cycle and males exhibit greater AVP
sensitivity to hypertonic saline infusion (Stachenfeld, Keefe, et al., 2001). Females have greater
water turnover compared to men in both phases of the menstrual cycle in response to a water
bolus (Claybaugh et al., 2000) suggesting influences of biological sex. Testing females during
the early follicular phase, may create a false assumption that females are, in fact, physiologically
like males. However, only testing female participants during the first four days of the menstrual
cycle (early follicular) only provides insight to physiological responses for <15% of the
menstrual cycle (Sims & Heather, 2018). Differences within phases of the menstrual cycle are
greater than those between sexes when comparing the osmotic threshold for AVP release
(Stachenfeld, Splenser, et al., 2001). Stachenfeld at al. (2001). demonstrated these differences in
within-sex and between-sex responses to a 3% NaCl infusion. Researchers found a lower
osmotic threshold for AVP release in the midluteal phase, when estrogen is higher than the
follicular phase, but no differences between sexes were present. These findings suggest that a
better understanding of both between-sex differences and within-sex differences in fluid balance
may be warranted for better hydration and overall health recommendations.
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The Menstrual Cycle and Fluid Balance
The primary sex hormones produced by the ovaries are estrogen and progesterone. These
ovarian hormones, along with hypothalamic hormones, influence the female reproductive system
and various other tissues (Constantini et al., 2005). Estrogen and progesterone peak and fall to
create what is known as the menstrual cycle. The menstrual cycle lasts ~28-32 days and consists
of three phases: the follicular phase (onset of bleeding to ovulation), the ovulatory phase (~day
14), and the luteal phase (~days 14-28). Each of these phases consists of varying hormone
concentrations. Further, they are associated with different responses to fluid loading and
retention, as well as mood states and sleep (Baker & Driver, 2007; Charkoudian & Stachenfeld,
2016; De Souza et al., 1989; Giersch et al., 2019; Sims & Heather, 2018; Stachenfeld, 2008;
Stachenfeld, DiPietro, et al., 1999; Stachenfeld & Taylor, 2014) During the follicular phase,
specifically the early follicular phase (days 1-4) of the menstrual cycle, estrogen and
progesterone are at their lowest concentrations. The middle of the cycle (ovulatory phase) is
characterized by peaks of estrogen, luteinizing hormone (LH) and follicular stimulating hormone
(FSH). The ovulatory phase is ~24 hours in length and although demonstrates surges in both LH
and FSH these hormones are not known to influence fluid balance. The luteal phase is
characterized by higher circulating levels of both estrogen and progesterone.
Hormones responsible for regulating TBW and Na+ balance also vary over the course of
the menstrual cycle. During the midluteal phase, plasma aldosterone concentration and plasma
renin activity are greater at rest and during exercise when compared to the follicular phase.
Resting plasma AVP concentration is directly related to plasma estrogen levels, as in the late
follicular phase and midluteal phase (De Souza et al., 1989) when estrogen levels peak. Resting
hematocrit, plasma estrogen, and plasma progesterone are greater in the luteal phase than in the
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follicular phase. However, plasma osmolality is lower in the luteal phase due to the downward
shifting of osmotic control (Stachenfeld, DiPietro, et al., 1999).
Estrogen and Progesterone Interaction with AVP on Fluid Balance
Both estrogen and progesterone influence renal and neural systems responsible for fluid
balance. Receptors for sex hormones are found in nonreproductive tissues involved in fluid
balance such as the kidney tubules, cardiovascular system and the hypothalamus (Sims et al.,
2008a; Stachenfeld, 2008) suggesting that sex hormones influence fluid balance systemically.
Fluid balance is further influenced by thirst, sodium appetite or satiety, renal fluid and sodium
regulation, all of which fluctuate throughout the menstrual cycle (Sims et al., 2008a). The renal
and neural systems are reactive to fluid deficits in the extracellular space due to sodium
concentrations, tonicity, or plasma osmolality. These systems are far more sensitive to osmolar
changes versus volume loss whereas a 2-3% change in plasma osmolality is needed to induce
thirst or an increase in AVP concentrations, whereas a 10% loss in plasma volume is required
before inducing an increase in AVP or thirst (Stachenfeld, 2008).
It is difficult to isolate the individual effects of estrogen and progesterone as both
hormones are elevated or decreased simultaneously during the menstrual cycle. Stachenfeld et
al., (2008) performed a series of studies using either a gonadotropin-releasing hormone (GnRH)
agonist or antagonist. This method suppressed estrogens, progesterone, and gonadotropins to
pharmacologically oophorectomize female subjects for a short time (Stachenfeld, Keefe, et al.,
2001; Stachenfeld & Keefe, 2002; Stachenfeld & Taylor, 2004, 2005a). In studies that used a
GnRH analog (leuprolide acetate), subjects were administered the drug continuously over two
weeks. Leuprolide acetate down regulates the hypothalamic-pituitary-ovarian axis so that plasma
concentrations of both estrogen and progesterone are undetectable within 14 days (Stachenfeld,
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Keefe, et al., 2001; Stachenfeld & Keefe, 2002, 2002). Other studies used a GnRH antagonist
(ganirelix acetate) which acts by competitively blocking the GnRH receptors on the pituitary
gonadotroph and therefore, induces a suppression of gonadotropin release and subsequently leads
to a decrease of both estrogen and progesterone to postmenopausal levels (Stachenfeld, 2008;
Stachenfeld et al., 2003; Stachenfeld & Taylor, 2005a). After the hormone suppression phase in
these studies, participants were dosed with estrogen only (estradiol), progesterone only or
combined hormones to better understand the individual or combined effects of sex hormones.
This allowed for within- and between-participant comparisons of osmotic regulation of AVP,
thirst, sodium and overall fluid regulation (Stachenfeld, 2008). Reproductive hormones (either
estrogen or progesterone) were given to participants post-GnRH suppression. After hormone
administration, a hypertonic saline infusion (3% NaCl) was administered. Estrogen
administration shifted the osmotic threshold for the release of AVP to a lower plasma osmolality
independently of progesterone. High levels of circulating estrogen increased the sensitivity for a
change in plasma osmolality needed to induce AVP release from the anterior pituitary
(Stachenfeld & Keefe, 2002; Stachenfeld & Taylor, 2004, 2005a). It is likely that the estradiol
related shift in osmotic regulation of AVP occurs via the central nervous system. Estrogens
cross the blood brain barrier and may influence AVP release at the hypothalamic level
(Stachenfeld, 2008). Estrogen lowering of the osmotic threshold for AVP release is likely due to
a downward shift of the osmoregulatory set point rather than a change in the fluid regulation.
The greater concentration of plasma AVP did not seem to contribute to fluid retention. There
were small increases in overall fluid retention during estradiol administration, renal free water
clearance was unaffected. This suggests that estrogens may alter renal sensitivity to AVP or
affect AVP action in the kidney (Stachenfeld, 2008).
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In further utilization of the GnRHa protocol, Stachenfeld at al., (2003) tested the
hypothesis that estradiol administration would attenuate the urine concentrating response when
compared to GnRHa administration without estradiol. When participants were infused with
synthetic AVP (pitressin), there was no estradiol effect on AVP-mediated renal concentrating
response. In the physiological range where AVP had the greatest renal concentrating effect, urine
osmolality was significantly decreased during estradiol treatment suggesting that greater
circulating estrogen attenuates the renal concentrating response (Stachenfeld et al., 2003).
While Stachenfeld et al., (2008) chose to isolate hormone expression to better understand
the individual responses attributed to both estrogen and progesterone, it is equally important to
understand hormone responses for applicability purposes. Although dehydration increases
plasma osmolality, it also decreases TBW, plasma volume and blood pressure (Stachenfeld,
DiPietro, et al., 1999). Using a hypertonic saline infusion creates a larger increase in plasma
volume, (16-20 mOsmol/kg H2O) allowing for the effects of estrogen to be dramatized and
therefore, better determined (Stachenfeld, 2008). Both methods are useful tools, but using a
hypertonic saline infusion lacks real world applicability as it pertains to female physiology in
sport or work environments where dehydration may be prevalent. Therefore, researchers have
investigated exercise induced dehydration and fluid restoration post-exercise (RodriguezGiustiniani & Galloway, 2019)
Considering, hormonal differences between the late follicular and midluteal phases on
fluid may impact fluid restoration balance due to the increase in estrogen during the midluteal
phase. Rodriguez-Giustiniani and Galloway (2019), studied eumenorrheic participants that
dehydrated via fluid restriction to 2% body mass loss. Participants completed an exercise trial in
the heat and following exercise dehydration, participants rehydrated with the equivalent of 100%
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body mass loss with a commercially available sports drink. Menstrual cycle phase did not affect
urine volume excreted, net fluid balance, sodium balance, urine osmolality or thirst intensity
(Rodriguez-Giustiniani & Galloway, 2019). Although this finding contradicts previous findings
that water retention increases during the luteal phase (Spruce et al., 1985; Stachenfeld, 2008;
Vokes et al., 1988), this study was the first to investigate acute rehydration post-exercise in the
heat in eumenorrheic females.
Sodium and Fluid Retention. The RAAS maintains blood volume and blood pressure by
regulating electrolyte levels and fluid balance (Komukai et al., 2010). Sex hormones seem to
govern RAAS as evident by the positive cardiovascular and renal health outcomes in
premenopausal women (Komukai et al., 2010). Estrogen-only therapy increases fluid retention
via RAAS by increasing plasma renin levels but, when combined with progesterone, this effect is
negated (Oelkers, 1996). Fluid dynamics are shifted as estrogen enhances vasodilation and
lowers the set point of plasma osmolality (Oelkers, 1996; Sims et al., 2008a; Stachenfeld, Keefe,
et al., 2001). Yet, progesterone competes with the same receptor that aldosterone binds to,
potentially leading to natriuresis. Stachenfeld et al., (1999) found that there was little change in
free water clearance during combined (estrogen and progesterone) administration similar to the
naturally occurring luteal phase and, although AVP concentration is greater in the midluteal
phase, the luteal phase is not associated with water retention (Calzone et al., 2001; Stachenfeld,
Silva, et al., 1999).
Overall changes in water and fluid retention are present during hormone administration.
These changes were of small magnitude and it is expected that the small amount of water
retention associated with estradiol administration may be due to an increase in sodium retention
rather than AVP mechanisms (Stachenfeld, Silva, et al., 1999; Stachenfeld & Keefe, 2002).
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Plasma renin activity was greater at baseline with estradiol administration, yet the greater plasma
renin activity did not continue with saline infusion nor was there an effect on aldosterone
suggesting that the increased Na+ retention associated with elevated estrogen is independent of
RAAS. There is conflicting evidence because others have reported that estradiol administration
may influence RAAS by enhancing angiotensin synthesis, inhibiting angiotensin-converting
enzyme activity and augmenting plasma and tissue levels of renin (Kuroski de Bold, 1999;
Oelkers, 1996; Stachenfeld, 2008). It is likely that the pathways through which hormones have
been delivered for research purposes (oral vs. transdermal) may have an effect on whether or not
RAAS is activated (Komukai et al., 2010). It is plausible that oral contraceptive use and
therefore, oral delivery of exogenous hormones, may result in a greater influence in RAAS
activation due to metabolism of oral contraceptives in the liver (Stachenfeld, 2008).
Proper sodium and electrolyte balance is important for maintenance of blood and plasma
volume (Sims et al., 2008a). Sims et al, (2008) investigated fluid balance, renal-sodium
sensitivity, and responses to a sodium concentrated beverage during hormonal extremes of the
menstrual cycle in eumenorrheic females and OC users. In a normal menstruating group,
participants were tested during the early follicular phase of the menstrual cycle (low hormone)
and the midluteal phase (high hormone). In the OC group, participants were tested during the
third week of a triphasic medication (high hormone) and during last week or placebo pill dosing
(low hormone). Participants consumed a sodium concentrated beverage (164 mmol/L) in the
amount of 10mL/kg body mass over the course of one hour, without an exercise component.
Plasma volume expansion was significantly different between menstrual cycle phase but not
between groups. The low hormone phases in both groups had greater plasma volume expansion.
AVP increased with sodium loading in the high hormone phase of both groups. Plasma
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osmolality was significantly different between phases. The AVP response in the high hormone
phases in both natural menstruating women and oral contraceptive users correlated with a lower
plasma osmolality. This study supported previous findings of decreased plasma osmolality with
elevated AVP when high hormones are present (Stachenfeld, 2008), regardless of pill use. Water
clearance was similar between groups with a lower water clearance in the high hormone phase of
both groups. High hormone phases also had higher urine osmolality and attenuated urine flow
volume. Sims et al. (2008) hypothesized it may be due to a resetting of osmoregulatory
mechanisms and the downward shift of plasma osmolality (Sims et al., 2008a). Further indicating
that fluid balance is maintained similarly between phases of the menstrual cycle but, during high
hormone phases, the cascade of events to induce fluid conservation begins at a lower plasma
osmolality (~281 mOsm/L vs. ~285 mOsm/L) (Sims et al., 2008a).
Oral Contraceptives and Fluid Balance
Oral contraceptives (OCs) are a group of exogenous steroidal sex hormones most
commonly prescribed for pregnancy prevention. They are effective in inhibiting ovulation by
suppressing luteinizing hormone secretion from the pituitary and thickening cervical mucous,
preventing endometrial development. While there are several methods of hormonal
contraceptives- combined OCs containing both estrogen and progesterone are the most
commonly prescribed and studied in young, athletic populations (Sims & Heather, 2018). Oral
contraceptives create synthetic hormonal control by promoting a negative feedback loop that
turns off the hypothalamic-pituitary-gonadal axis preventing endogenous estrogen or
progesterone release (Sims & Heather, 2018). Therefore, circulating exogenous sex hormone
concentrations are set by the daily dose of prescribed medication. The synthetic hormones mimic
endogenous hormones but vary greatly in the pathway of entry into the bloodstream. The
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circulating hormone concentrations and molecular structure and bioactivity may act on receptors
differently than naturally occurring steroids (Sims & Heather, 2018).
Long term OC use may cause adaptation in the fluid balance system. OCs exhibit 3-10
times the bioactivity of endogenous estrogen in combined (estrogen and progesterone OCs)
(Sims & Heather, 2018; Stachenfeld, Silva, et al., 1999), but the progestin component of OCs do
not compete with the same receptor as aldosterone, unlike endogenous progesterone. Therefore,
ethinyl estradiol (synthetic estrogen) may induce fluid expansion to a greater degree than
endogenous hormones. Circulating angiotensin is synthesized primarily by the liver and orally
administered estradiol is metabolized by the liver. Increases in plasma angiotensin and
aldosterone may be a consequence of oral estradiol administration (Stachenfeld, 2008).
To determine estrogen effects from OC use, Stachenfeld et al., (1999) administered OCs
(combined progesterone and estrogen OCs and progesterone only OCs) to young women and
evaluated responses to exercise dehydration and a rehydration period. They found that OCs
containing estrogen (combined hormone OCs) increased osmotically induced AVP and thirst
during dehydration and ad libitum rehydration even though there were no changes in water
retention (Stachenfeld, Silva, et al., 1999). Confirming the hypothesis that estrogen is responsible
for shifting the plasma osmotic threshold to a lower set point.
Future Considerations in Fluid Balance Research
Estrogen and progesterone affect body fluid and sodium regulation. Primarily, they act by
shifting the set point for osmotic regulation and AVP release in multiple conditions including
exercise induced dehydration, oral fluid loading and osmotic stimulation via hypertonic saline
infusions (Stachenfeld, 2008). The difference in osmoregulation seems has minimal effects on
TBW and sodium retention, but changes the body water distribution within the extracellular
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space (Stachenfeld, Keefe, et al., 2001). In future studies, the influence of sex hormones will be
important considerations in understanding the regulation of water and sodium (Sims & Heather,
2018; Stachenfeld, 2008). Influences may be particularly important in individuals with differing
conditions such as, susceptibility to hyponatremia, pregnancy, pre-menarche, or post-menopause.
Fluid and electrolyte balance are critical for normal cellular function and maintenance of both
blood and plasma volume. The interactions of female sex hormones and the fluid regulatory
system is crucial. OCs will continue to evolve as pharmacological technology advances and new
methods of hormonal contraceptives emerge; therefore, it is important to continue research into
female endogenous and exogenous hormones and their effects on TBW and fluid balance.
Further research is needed to make best practice recommendations and positively contribute to
women’s health.
Exercise in the Heat and Importance of Fluid Balance
Exercising in the heat requires cardiovascular and thermoregulatory adjustments to
maintain both core body temperature and mean arterial pressure (González-Alonso et al., 2000;
Montain et al., 1995; Montain & Coyle, 1992; Sawka et al., 2001; Wendt et al., 2007). At the
onset of exercise, feed-forward signals from central command indicate an increase in heart rate
and blood pressure to maintain blood flow to the brain and working musculature.
Vasoconstriction in the cutaneous vasculature aids in the maintenance of central venous pressure.
As exercise continues, especially in the heat, blood flow to the periphery and sweating increase
as core temperature and skin temperature rise to cool the body (Nadel, 1979; Nadel, Bullard, &
Stolwijk, 1971; Rowell, 1974; Sawka et al., 2011). The redistribution of blood causes a
subsequent reduction in central blood volume. To maintain cardiac output (Q), heart rate and
cardiac contractility are increased (Rowell, 1974). As intensity increases during exercise in the
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heat the competition for blood flow between the cutaneous and skeletal muscle vasculature
induces greater cardiovascular strain. As a result, performance is attenuated, particularly during
endurance events (Cheuvront, Roberts, & Montain, 2007; Sawka et al., 2011).
There is substantial impairment in stroke volume due to blood volume reductions when
exercise is combined with dehydration (González-Alonso et al., 2000). Q is reduced compared
to a euhydrated state (González-Alonso et al., 1997). The attenuation in Q results in a reduction
in muscle blood flow leading to sacrificed performance (Casa et al., 2010; González-Alonso et
al., 1998). Dehydration impairs skin blood flow and sweating (González-Alonso et al., 2000).
Therefore, there is a decreased ability to dissipate heat, resulting in elevated core temperatures
during exercise compared to a euhydrated state (Casa et al., 2010; Cheuvront & Kenefick, 2014;
González-Alonso, Mora-Rodríguez, Below, & Coyle, 1995; González-Alonso et al., 1997).
Female Hormones and Thermoregulation
Like fluid balance and hydration research, few studies in thermoregulatory physiology
have included females due to perceived sex hormone differences. (Hutchins et al., 2021; Kolka
& Stephenson, 1997b). In previous studies the results are inconsistent with the impact of
menstrual cycle phase on thermoregulation (Giersch et al., 2020). It is likely that sex steroids
affect thermoregulation by changing the overall regulated hypothalamic temperature, or
thermoregulatory “set-point” (Stachenfeld et al., 2000) and animal studies have shown that
estrogen and progesterone act on sex steroid binding neurons in the preoptic, anterior
hypothalamus (Silva & Boulant, 1986). Progesterone decreases the firing rate of preoptic warm
sensitive neurons and increases the firing rate of preoptic cold sensitive neurons (Kolka &
Stephenson, 1997a). Concomitantly, progesterone is highest during the luteal phase of the
menstrual cycle and is associated with an increase in core body temperature of 0.3-0.8°C at rest
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(Baker et al., 2020; Charkoudian & Johnson, 1999; Charkoudian & Stachenfeld, 2016;
Constantini et al., 2005; Kolka & Stephenson, 1989; Pivarnik et al., 1992; Rogers & Baker,
1996). Estrogen may modify temperature increases associated with progesterone even though the
mechanism by which body temperature is affected has not been established (Stachenfeld et al.,
2000). During the midluteal phase, both estrogen and progesterone are elevated, yet,
progesterone dominates the effects of estrogen on overall body temperature (Charkoudian et al.,
2017). Regardless of mechanism, temperature thresholds for sweating and vasodilation during
exercise and resting core body temperature are greater in the midluteal phase, when progesterone
concentrations are greater, than in the follicular phase (Charkoudian & Stachenfeld, 2016; Kolka
& Stephenson, 1997a, 1997b, 1997b). Observations support an upward (rightward) shift in a
thermoregulatory set-point and higher regulated set body temperature during the luteal phase
(Giersch et al., 2020). It is important to note that this set-point shift does not happen if ovulation
does not occur. Meaning that without ovulation, a rise in progesterone and estrogen responsible
for the set-point shift, would not be present (Kolka & Stephenson, 1997a; Stachenfeld et al.,
2000). Theoretically, the rightward shift in a thermoregulatory set-point could affect female’s
ability to thermoregulate and effectively cool during work in the heat during the luteal phase of
her menstrual cycle (Pivarnik et al., 1992). An already elevated core temperature could make a
person more susceptible to uncompensable heat stress. The potential for heat illness and
performance decrements would be observed. An attenuation in sweat sensitivity or an overall
decrease in total sweat losses would increase risk of heat illness. Several studies have
investigated the thermoregulatory effects between the midluteal and follicular phases of the
menstrual cycle.
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In both resting (Kolka & Stephenson, 1989) and exercise conditions (Kolka &
Stephenson, 1997b), the threshold for skin vasodilation and the onset of sweating occur at a
higher esophageal temperature during the midluteal phase when compared to the early follicular
phase. Observations are evident in non-acclimatized but regularly exercising females. In one
study, the average esophageal temperature for the onset of sweating at the forearm was 36.91°C
during the follicular phase and 37.45°C during the luteal phase (Kolka & Stephenson, 1989).
Interestingly, some studies have found no difference in sweat rates, overall sweat loss (Carpenter
& Nunneley, 1988; Haslag & Hertzman, 1965; Pivarnik et al., 1992), or mean weighted skin
temperature between the midluteal and early follicular phases (Kuwahara et al., 2005; Lei et al.,
2017; Pivarnik et al., 1992). Kuwahara et al. (2005) showed that cutaneous blood flow and sweat
rate were significantly less in the midluteal phase than in the mid-follicular phase, but this was
only demonstrated in an untrained group of participants, and there were no differences in trained
females.
Skin temperature is important for heat loss and, when skin temperature is greater than the
environmental temperature, it allows for heat loss due to an increased temperature gradient. The
increased gradient allows for a greater evaporative capacity and more efficient cooling via sweat
loss (Wendt et al., 2007). During the midluteal phase, the greater threshold in vasodilation
decreases skin blood flow (Carpenter & Nunneley, 1988; Charkoudian & Stachenfeld, 2016).
During the midluteal phase, females experience increased core temperatures, hotter skin
temperatures and decreases in sweat rate. During exercise in the heat, heart rate will increase to
maintain CO and therefore, heart rate will be elevated during the midluteal phase when
compared to the early follicular phase (Pivarnik et al., 1992). Pivarnik et al. (1992) demonstrated
that during 60 minutes of exercise at 65-70% VO2peak, heart rate was 10 bpm lower during the
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follicular phase than the midluteal phase. However, rather than environmental conditions,
intensity and duration were used as a heat load (Pivarnik et al., 1992).
Oral Contraceptives and Thermoregulation
According to the National Center for Health Statistics data from the 2015-2017 National
Survey of Family Growth, 64.9% of the 72.2 million women aged 15-49 in the U.S were using
contraception (Daniels, 2015). Of the reversible methods of contraception, the most common
was the use of oral contraceptive pills (12.6%) within the previously mentioned age range
(Daniels, 2015). Stachenfeld et al. (Stachenfeld, 2018) further reported that > 90% of European
and U.S. females are either currently taking or have previously taken oral contraceptives. In
athletes, the prevalence of females taking combined, monophasic oral contraceptives is 50% (Lei
et al., 2019). Oral contraceptive use follows the same patterns as the natural menstrual cycle by
creating a pseudo-cycle of high and low hormone concentrations. In thermoregulatory
investigations, OC use has been compared to normal menstruating females but exogenous
hormones are not the same as endogenous hormones (Pivarnik et al., 1992; Sunderland & Nevill,
2003; Tenaglia et al., 1999). It is possible exogenous estrogen may attenuate the
thermoregulatory effects of progestin (synthetic progesterone) due to estrogens effect on
thermosensitive neurons in the central nervous system (Stachenfeld et al., 2000).
In oral contraceptive users, baseline core temperature is significantly greater during the
midluteal phase due to the higher concentration of progesterone.(Lei et al., 2019; Rogers &
Baker, 1996; Tenaglia et al., 1999). Rogers and Baker (1996) found that core temperature was
0.31°C higher during OC use (high hormone) when compared to the placebo week (low
hormone) in long-term OC users. The elevated core temperature in OC users is similar to the
elevated core temperature of eumenorrheic females in the midluteal phase (Tenaglia et al., 1999).
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Core temperature remains elevated during moderate exercise in both untrained and trained
participants who take OCs (Lei et al., 2019; Rogers & Baker, 1996). Long-term OC users may
have an attenuated sweat response (onset of sweating and thermosensitivity) during exercise in
the heat (Kuwahara et al., 2005; Lei et al., 2019) whereas, the onset of sweating occurs at a core
temperature of 37.8°C (0.6°C) during active pill dosing versus 37.48 (0.4°C) the placebo week.
(Rogers & Baker, 1996). Findings support the thermoregulatory set point shift is present with
oral contraceptive use (Charkoudian & Johnson, 1999; Lei et al., 2019; Stachenfeld et al., 2000).
Environment, Hydration and Training Status
Heat loss is affected by menstrual cycle phase and environmental factors. Even more so,
by the combination of phase and environment. The largest determinant in work capacity is
evaporative capacity or humidity and heat (Lei et al., 2017). Work capacity determined by mean
power output is similar between menstrual cycle phases but greater in dry conditions than humid
conditions (T. Lei et al., 2019a). In both OC users and eumenorrheic females, there is a
thermoregulatory vs. performance trade off that ensures thermoregulation is not impaired with
the sacrifice of attenuated performance (Lei et al., 2019). In hot environments, core temperature
is elevated throughout aerobic exercise independently of menstrual cycle phase. In hot, humid
environments the rate of rise of core temperature is 19% greater during the luteal phase and
exercise time to exhaustion is significantly longer during the follicular phase (5.7%) in
eumenorrheic women (Janse De Jonge et al., 2012). The rate of perceived exertion (RPE) is also
greater during the luteal phase (Janse De Jonge et al., 2012; Lei et al., 2017; Pivarnik et al.,
1992). Time to exhaustion and core temperature do not differ between phases during exercise in
a temperate environment (Janse De Jonge et al., 2012; Pivarnik et al., 1992.).
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A greater training status may alleviate the greater core temperatures associated with high
hormone phases. Kuwahara et al. (2005), found that menstrual cycle phase had no effect on heat
loss responses in trained participants. Esophageal temperatures of trained participants are lower
during the midluteal phase when compared to an untrained cohort. However, the temperature
differences are not evident during the follicular phase between untrained and trained participants
(Kuwahara et al., 2005) Heat loss responses were improved by long-term physical training
suggesting that a greater training status may attenuate heat storage during the midluteal phase
(Kuwahara et al., 2005). However, it should be noted that basal body temperature was used to
determine menstrual cycle phase, a method shown to not be as reliable as plasma samples when
used as a one-time measure (Giersch et al., 2020).
The rate of rise of core temperature in dehydrated women is greater than in dehydrated
men during the first stages of exercise (Giersch et al., 2021). Therefore, women may be more
affected in the early stages of exercise in the heat when dehydrated than men. During moderate
intensity exercise (50% VO2peak for 90 minutes) in hot conditions (30 ± 2°C, 50 ± 5% RH) ,
rectal temperature is greater in the high progesterone phase than in the low progesterone phase.
Without water consumption, rectal temperature is greater by 0.4°C during the high progesterone
phase. With water consumption, rectal temperature during the high progesterone phase is greater
than the low progesterone phase by 0.2°C (Hashimoto et al., 2016). Heart rate is significantly
greater without water consumption during the high progesterone phase (Hashimoto et al., 2016)
Water consumption may useful for suppressing the increase in body temperature associated with
greater progesterone as is in the midluteal phase (Hashimoto et al., 2016) and may attenuate the
increased core temperature associated in the luteal phase (Garcia et al., 2006). Despite
differences in pre- and during- exercise hydration status, post-exercise rehydration does not seem
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to be affected by menstrual cycle phase (Rodriguez-Giustiniani & Galloway, 2019). Although
menstrual cycle phase may be responsible for some physiological differences during exercise in
the heat (higher resting core temperature) it may be more likely that hydration status and
environmental factors may have a greater impact on physiological outcomes.
Importance of Including Females in Research
Few studies have investigated thermoregulatory responses across the entirety of the
menstrual cycle including the low hormone concentrations of the early follicular phase, the peak
in estrogen in the late follicular phase and the midluteal phase where both estrogen and
progesterone concentrations are concomitantly increased. The menstrual cycle phase is often
controlled for during the follicular phase, when circulating sex hormones are at their lowest
concentration. In theory, this allows for comparisons between sex when males are included in the
research design. However, it is inappropriate as it fails to investigate the changing hormone
profile over the female menstrual cycle as well as those taking oral contraceptives. An increase
in heart rate or RPE could affect sport or work performance (Constantini et al., 2005) especially
in hot and humid environmental conditions. In some military settings, heat intolerance is defined
as a peak rectal temperature of 38.5 °C, a peak heart rate > 150bpm or the inability to reach
equilibrium at these values. Using this criterion, 67% of female participants are classified as
“heat intolerant” compared to 33% of males (Druyan et al., 2012). Although females do not
exhibit symptoms of heat stress indicating that the criteria for determining heat intolerance in
females should be reconsidered (Druyan et al., 2012). Furthermore, there may be practical
recommendations for endurance athletes to align competition with menstrual cycle phase
especially in hot, humid conditions (Janse De Jonge et al., 2012; Sunderland & Nevill, 2003).
Training responses may be dependent on RPE and heart rate and may vary with menstrual cycle
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phase (Janse De Jonge et al., 2012). A better understanding of female thermoregulation may lead
to advantages in sport and work performance, establish better criteria for determining heat
intolerance and potentially lead to better safety guidelines as more females play sports, join the
military or occupational workforce.
Gaps in Literature and Methodological Considerations
Several studies have sought to identify the effect of menstrual cycle on thermoregulatory
effects (Giersch et al., 2020; Lei et al., 2019; Lei et al., 2017; Notley et al., 2019). Few studies
have strong methodologies. At the very least, studies have failed to measure the same main
outcome variables for comparison or have found conflicting evidence. Poor methodological
considerations have led to an unclear consensus on thermoregulatory response across the
menstrual cycle. Giersch et al. ( 2020) aimed to summarize findings in a meta-analysis of nine
studies (sample size determined by hormone concentrations verified by plasma sample). During
the luteal phase, eumenorrheic female participants had a greater initial internal temperature
compared to the follicular phase, but differences were absent during and post-exercise (Giersch
et al., 2020). Further, there were no differences in mean skin temperature, sweat rate or exercise
heart rate between phases in eumenorrheic females (Giersch et al., 2020). Because of these small
but significant findings in resting conditions, researchers should explore thermoregulatory
responses in exercise under differing environmental conditions. Especially, conditions that
induce uncompensable heat stress such as, heat and humidity should be considered. The effects
of exogenous hormones should be explored concomitantly with exercise in heat and humidity.
Study Design
Both Elliot-Sale et al. (2021) and Heather and Sims (Sims & Heather, 2018) have set
forth best practice methodologies of studying females in exercise physiology. Stating the need
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for hormone concentration status validation via blood draw, OCP use in study design, and
applicable considerations.
Control of menstrual cycle. More often than not, menstrual cycle status or the hormonal profile
of the participant is often implied rather than confirmed. (Elliott-Sale, 2021.; Giersch et al.,
2020) It is necessary for the literature to become consistent in the terminology used to describe
participants and the inclusion and exclusion criteria used to define participant eligibility (ElliottSale, 2021). In research questions that involve the effect of ovarian steroids, for instance, the
effect of high progesterone levels (midluteal phase) on hydration or thermoregulation the
quantification of sex steroid concentration should be reported via blood analysis (Elliott-Sale,
2021) especially, due to the lack of a rightward thermoregulatory shift without ovulation
(Giersch et al., 2020; Stachenfeld et al., 2000).
Oral contraceptives. Endogenous and exogenous hormones are not the same, which adds
complexity to study design (Stachenfeld, 2018). In research design, it should be considered that
OC taking days (active pills) and OC-free days (inactive, placebo, sham pills) that the
endogenous concentration of estrogen and progesterone rises during the OC-free days and the
exogenous hormones increases during the active OC dosing. While taking a combined
monophasic OC, ethinyl estradiol increased twofold from day 1 of active pill dosing to day 21
and progestin increases threefold from day 1 of active OC to days 8-11 and then maintains that
level of concentration (Elliott-Sale, 2021). Therefore, it is important to establish a study design
that takes the concentration levels into consideration if concentrations affect main outcome
variables. It is possible comparing the active OC dose with the inactive dose is not a best practice
because the inactive dose is more reflective of a transient hormone phase due to varying half
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lives (Sims & Heather, 2018). However, with a large portion of the female population taking
OCs this research is still applicable to better understand physiological outcomes.
Hydration
In several of the aforementioned studies, hydration status was not controlled for or
quantified during exercise (Janse De Jonge et al., 2012; Kolka & Stephenson, 1989, 1997b;
Kuwahara et al., 2005; Pivarnik et al., 1992.). It is well known dehydration is deleterious to
performance and thermoregulatory effects (Bardis et al., 2013; José et al., 1997; Montain &
Coyle, 1992). These studies have become more indicative of a model for dehydration and
exercise in the heat rather than thermoregulatory differences. Further complicating the
assessment of sex hormones and thermoregulation. Matched conditions help to compare phases
of the menstrual cycle but do not negate the outcomes that may be affected by dehydration (lack
of heat dissipation, increased heart rate, sweat rate, total sweat loss). Females may be more
susceptible to the effects of dehydration prior to exercise in the heat (Giersch et al., 2021).
Therefore, it is important to control for hydration status to isolate the effects of sex hormones on
thermoregulation.
Summary
Overall, there is evidence that female sex-hormones affect both fluid balance and
thermoregulation. Estrogen and progesterone may have individual effects on physiological
mechanisms but when both concentrations are high, as seen in the post-ovulatory, midluteal
phase, these hormones may act concomitantly and in balance with one another. OCs are taken by
many females and should be part of ever- evolving research. Guidelines and practices should
consider significant differences that may found regarding sex and sex hormones these differences
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for best outcomes. If significant differences are not present, the exclusion of female participants
in exercise physiology studies is unwarranted.
Key Takeaways
-

Menstrual cycle phase and related hormone fluctuations affect neural and hormonal systems that
influence fluid regulatory systems

-

Estrogen shifts osmotic threshold for AVP release to the left, meaning that AVP is released
at a lower osmolality when estrogen concentration is greater

-

Progesterone shifts thermoregulatory control to the right, causing core body temperature to
be greater at rest

-

Oral contraceptives continue to evolve and therefore, researchers should continue to
investigate exogenous hormone influences on both fluid balance and thermoregulation.
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III. Methods
Eleven healthy, aerobically trained (VO2peak > 45 ml/kg/min), female long term ( > 3
months, Elliott-Sale, 2021) oral contraceptive users were recruited from the University and
surrounding areas to participate in this crossover, counterbalanced design study. All procedures
were approved by the University Institutional Review Board and written informed consent was
obtained from all individuals prior to study participation and data collection. Participants
completed a total of five visits including one pre-test to establish VO2peak and familiarization of
the exercise protocol, two experimental days (one on active pill dosing of oral contraception and
one on her non-active pill dosing), and two quick visits to drop off urine containers postexperiment. Trials were scheduled so that the participant was on her dosing for at least 48-h prior
to data collection. Trials were scheduled at least 7 days apart to avoid acclimatization. One trial
was scheduled during the third week of active pill dosing, and the other during the placebo
dosing. Exclusionary criteria included previous heat exhaustion or heat stroke within the past
three years, current musculoskeletal injury, hypertension where vigorous exercise is
contraindicated, diagnosed sickle cell trait, use of medications that may alter thermoregulation or
fluid balance, and use of tobacco or vaping. All participants were asked to refrain from alcohol
use for 24-h, caffeine for 12-h, and vigorous exercise for 24-h prior to each trial. Body
composition was assessed via dual energy x-ray absorptiometry (DXA, Lunar Prodigy, General
Electric, Madison, WI, USA).
Familiarization Day
During the familiarization visit, participants signed an informed consent form and
complete a medical history questionnaire. Baseline demographic information was collected
(height, weight, body surface area) and body composition was assessed via DXA. Participants
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underwent a graded exercise test on a cycle ergometer to assess peak oxygen uptake (VO2peak)
and, due to the linear relationship between VO2 and work rate, to establish exercise intensities for
subsequent trials (55% of max wattage attained). VO2peak was assessed via a graded exercise test
(GXT) on a Velotron Dynafit Pro cycle electronically braked cycle ergometer (Racer Mate,
Seattle, WA). Prior to testing, seat and handlebar preferences were established for each
individual and recorded for use in all future testing sessions. Participants were instrumented with
a Polar heart rate monitor (FT1/T31, Polar Inc, Lake Success, NY, USA). Subjects warmed up at
100 W for 2 minutes at a self-selected cadence. Upon completion of the warm-up, the resistance
increased by 25 W in 2-minute intervals until the participant could no longer maintain 60
revolutions per minute (RPM) on the ergometer or reached volitional fatigue. VO2peak was
measured using breath-by-breath analysis and analyzed via open-circuit spirometry (PARVO
Medics, Sandy, UT). The two highest consecutive 15-second VO2peak values recorded were used
as the peak measurement provided it meets at least two of the following criteria: a) a plateau in
heart rate or heart rate is within 10% of the age predicted maximum, b) a plateau in VO2peak (an
increase of no more than 150 ml∙min 1), and/or c) an RER value > 1.15. Following their VO2peak
assessment, participants were familiarized with the heat chamber and experimental protocol.
During this time, participants were also informed on the perceptual scales for rating of perceived
exertion (RPE) (Borg, 1970), thermal sensation (Toner, Drolet, & Pandolf, 1986), and perceived
thirst (Engell et al., 1987)
Experimental Days
Participants reported to the Exercise Science Research Center after having a light meal 2
hours prior (matched between trials). Upon arrival, participants completed a 24-h history
questionnaire, provided a spot urine sample, and completed a nude body mass. The spot urine
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sample was analyzed for urine specific gravity (USG, refractometer, model Master-SUR,NM,
Atago Co Ltd, Tokyo, Japan) and osmolality (freezing point depression, Model 3250, Advanced
Instruments Inc., Norwood, MA) to confirm hydration status. Participants could begin their trial
if they were euhydrated confirmed by USG (< 1.020). If participant’s USG was >1.020, 500mL
of water was provided prior to trial start. A blood draw via venous venipuncture was taken for
later analysis of copeptin and aldosterone concentration and quantification of plasma volume
change. Participants were provided a rectal thermometer (RET-1, Physitemp Instruments Inc,
Clifton, NJ, USA) to insert ~15 cm past the anal sphincter to assess rectal temperature (Trec).
Participants were instrumented with electrodes and an automated blood pressure cuff (Tango+,
Suntech, Medical Inc., Morrisville, NC, USA) and skin temperature thermochrons (iButton,
Maxim Integrated, San Jose, CA, USA) to assess four-site mean weighted skin temperature (Tsk)
(Ramanathan, 1964). Sweat patches (Tegaderm+Pad, 3M, St. Paul, MN, USA) to assess sweat
electrolytes were applied to the dorsal forearm. Participant attire consisted of running shorts or
cycling bibs, sports bra, socks, and shoes (matched between trials). Participants transitioned to
an environmental chamber (30°C, 55% relative humidity) and completed a 10-minute up-right
seated acclimation period. Physiological and perceptual measures were assessed at the end of
the ten minutes. Body mass was obtained, and the participant mounted the cycle ergometer. The
cycle ergometer was positioned on a scale to measure changes in body mass due to sweat loss.
Once comfortable on the ergometer, the participants began 90 minutes of exercise at 55% of the
wattage attained during the final stage of the VO2peak test. Trec, heart rate, blood pressure and
perceptual measurements were recorded every 15-minutes. Body mass change was measured
continuously and recorded every 15-minutes and subsequently used to provide water (warmed to
38°C) to replace sweat losses. Water was given to the participant to match 50% of sweat loss at
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each time point. Participants finished drinking the water over the subsequent 15-minutes.
Metabolic data including oxygen consumption (VO2 and the respiratory exchange ratio (RER),
wattage and cadence was collected at 30-minutes, 60-minutes, 75-minutes and at the cessation
of exercise (Hashimoto et al., 2016) to ensure work intensity was kept constant. Following
exercise, participants completed a self-selected cool down for 2-3 minutes while remaining on
the cycle ergometer. They got off the cycle ergometer and moved to a seated position where they
recovered until 30-minutes post-exercise. The participants then exited the chamber, removed
instrumentation, and provided a final nude body mass, urine sample and blood sample.
Participants were provided 125% of sweat lost in fluids and a recovery beverage
(P:26g/CHO:6g/F: 4.5g; CorePower, fairlife LLC, Chicago, IL, USA) and water to consume
within 60 minutes but were asked to refrain from any other fluid or food intake. They were
provided urine jug containers to collect their urine over the following three hours post-fluid
consumption and asked to record thirst, sense of urgency, and time of urination on the container.
Participants provided a forced urine sample at 3-hours post-trial in a separate urine container.
Participants brought urine collection jugs back to the laboratory later that same day or the
following morning. Urine samples were used to assess 3-hour USG, volume, and urine
osmolality.
Blood Analysis
Blood was collected pre-exercise trial and post-exercise trial. Serum collected at each
time point clotted at room temperature followed by centrifugation at 1000g and 4°C for 15
minutes. Serum was used to assess osmolality via freezing point depression and electrolytes (ionselective electrode, EasyElectrolyte, Medica Corporation, Bedford, MA, USA) in duplicate.
Plasma collected at each time point was used to assess hemoglobin (Hb) in duplicate
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(HemoCueHb 201+, HemoCue, Angelholm, Sweden) and hematocrit read in triplicate using
microcapillary tubes with a Micro-Capillary Reader (International Equipment Company,
Needham Heights, MA).
Statistical Analysis
All statistical analyses were completed using jamovi 2.2.5. A repeated measures
multivariate analysis of variance was used to assess Trec, heart rate, blood pressure, and mean
weighted skin temperature. Normality was assessed via Shapiro-Wilks’s test and outliers were be
removed if necessary. Statistical analyses were completed with and without outliers removed to
identify the impacts on outcomes. If the outliers did not impact the findings, the outliers were
removed, and results reported. Analyses requiring outlier removal (i.e., decreasing sample size)
is noted in the results. When sphericity was violated, Hyunh-Feldt adjustments were used in the
omnibus test. Post-hoc analyses involved pairwise comparisons with an appropriate Bonferroni
corrected alpha to identify significant time point differences. Data that failed normality (muscle
pain and change in Tre) was treated as normal due to skewness < 2. Alpha of 0.05 was set a
priori to determine significance at the omnibus level. Based on a 0.80 power calculation using
core temperature as the primary outcome variable with a correlation between time points of 0.5,
a 2-standard deviation effect size, β of 0.20, and α of 0.05, it was determined 8 participants
would be sufficient to complete this study. An increased experiment-wise type I error rate is
acknowledged due to the multivariate and univariate analyses conducted.
IV. Results
Descriptive information for participants is displayed in Table 1. There were no significant
differences in kcal (ACT: 1849 ± 783 kcal; PLA: 2128 ± 621 kcal, t10 = -0.919, P = 0.380),
carbohydrate (ACT: 206 ± 100 g; PLA: 212 ± 58g , t10 = -.217, P = 0.833) protein (ACT: 78 ± 39
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g, PLA:100 ± 35 g, t10 = -1.975, P = 0.077) or fat intake (ACT: 83 ± 50 g ; PLA: 100 ± 35 g , t10
= -0.943, P = 0.368) in the 24-h preceding trials. There were no significant differences in wet
bulb globe temperature (WBGT) over time (F1,10 = 2.275, P = 0.162), between trials (F2.90,28.95 =
2.275, P = 0.162), or time x trial interaction (F2.95,29.56 = 2.373, P = 0.091). By design, VO2
was not significantly different over time (F3,30 = 1.340, P = 0.280), between trials (F1,10 = 0.163,
P = 0.695), nor was there a time x trial interaction for VO2 measures (F3,30 = 1.825, P = 0.164,
grand mean: ACT 32.6 ± 3.0 mL/kg/min; PLA 32.4 ± 3.0 mL/kg/min). Metabolic heat
production was not different between trials (ACT: 9.37 ± 0.8 W/kg; PLA: 9.29 ± 0.74 W/kg,
t10 = 0.508, P = 0.622) and participants cycled at 68 ± 6% of their VO2 peak.
Hydration
There was a significant main effect for nude body mass (NBM) to decrease over time
from pre-trial (ACT: 59.59 ± 5.88 kg, PLA: 59.46 ± 5.30 kg) to post-trial (ACT: 58.85 ± 5.81 kg
vs. PLA: 58.85 ± 5.31 kg), regardless of trial (F1,10 = 55.420, P < 0.001). NBM was not different
between trials (F1,10 = 0.042, P = 0.842) nor was there a time x trial interaction (F1,10 = 1.190, P =
0.301).
Pre-trial spot USG (ACT: 1.011 ± .008; PLA: 1.011 ± .007) was not significantly
different between trials (F1,8 = 0.130, P = 0.728). Likewise, post-trial USG was similar between
trials (ACT: 1.013 ± .005; PLA: 1.013 ± .004, F1,8 = 0.084, P = 0.780). There was not a time x
trial interaction (F1,8 = 0.032, P = 0.864) for USG. Pre-trial urine osmolality (ACT: 384 ±299
mosm•L-1; PLA: 416 ± 387 mosm•L-1) was not different compared to post-trial (ACT: 413 ±
170 mosm•L-1; PLA: 411 ± 165 mosm•L-1, F1,8 = 0.217, P = 0.654) and was not different
between trials (F1,8 = 0.008, P = 0.930) nor was there a trial x time interaction (F1,8 = 0.047, P =
0.834).
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Thermoregulation
Tre demonstrated a significant main effect difference for ACT to be greater than PLA,
regardless of time point (F1.55,15.53 = 74.019, P < 0.001). There was also a significant main effect
for Tre to increase over time, regardless of trial (F1,10 = 24.064, P < 0.001). There was not an
interaction of time x trial (F1.96,19.62 = 1.822, P = 0.189) for Tre. There was no difference in overall
change in temperature (baseline to maximum temperature) between trials (ACT: 1.3 ± 0.5ºC,
PLA: 1.4 ± 0.4ºC, t10 = -0.588, P = 0.570). Data for Tre throughout trials is presented in Figure
1A.
Regardless of trial, Tsk significantly increased over time (F6,24 = 2.595, P = 0.044) but there was
no difference between trials (F1,4 = 0.902, P = 0.396). There was no time x trial interaction for
Tsk (F6,24 = 0.856, P = 0.540). Baseline Tsk was significantly lower than all other time points (P =
0.002). There were no other time point differences with Tsk (P > 0.877).
Total sweat loss was not different between trials (ACT: 1145 ± 189 mL; PLA: 1041 ±
275 mL, t10 = 2.064, P.= 0.066; Figure 2) nor was sweat rate (ACT: 764 ± 126 mL/hr; PLA: 694
± 183 mL/hr, t10 = 2.064, P = 0.066). There was no difference in percentage body mass loss
between trials (ACT: 1.2 ± 0.5%, PLA: 1.1 ± 0.6%, t10 = 0.834, P = 0.424).
Perceptual Measures
Perceptual measures are shown in Figure 4, A-D. RPE demonstrated a main effect for
increasing over time, regardless of trial (F2.115,21.153 = 106.286, P < 0.001). There was a
significantly greater RPE during the ACT trial (F1,10 = 11.250, P = 0.007), regardless of time
point. There was not a significant time x trial interaction for RPE (F2.716,27.162 = 1.894, P = 0.159).
Thermal sensation demonstrated a main effect for increasing over time, regardless of trial
(F2.32,23.23 = 22.669, P < 0.001). There was no significant difference between ACT and PLA trials
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(F1,10 = 0.676, P = 0.430) nor was there a time x trial interaction (F3.96,39.56 = 0.555, P = 0.694)
with thermal sensation. Thirst increased over time, regardless of trial (F2.62,26.23 = 29.045, P <
0.001). There were no significant thirst differences between ACT and PLA trials (F1,10 = 1.861, P
= 0.202) nor was there a time x trial interaction (F4.57,45.67 = 1.659, P = 0.169). Muscle pain
increased over time, regardless of trial (F1.53,15.30 = 13.716, P < 0.001). There was no significant
difference between ACT and PLA trials (F1,10 = 0.2.185, P = 0.170) nor was there a time x trial
interaction (F3.0,30.03 = 0.663, P = 0.581) for muscle pain.
Cardiovascular measures
Heart rate increased over time, regardless of trial (F1.572,14.146 = 483.74, P < 0.001) but
there was no difference between trials (F1,9 = 2.146, P = 0.176). There was no time x trial
interaction for HR (F3.275,29.47 = 1.344, P = 0.254). Data for HR throughout trials is presented in
Figure 3A.
Mean arterial pressure increased over time, regardless of trial (F6,24 = 3.378, P = 0.015),
but there was no difference in MAP between trials (F1,4 = 0.763, P = 0.432). There was not an
interaction effect for MAP (F6,24 = 0.765, P = 0.605). Data for MAP throughout trials are
presented in Figure 3B.
Blood Analysis
Blood markers of hydration are presented in Table 2. There was no time x trial interaction
for plasma osmolality (F1,8 = 0.917, P = 0.363). There was not an interaction effect of time x trial
for plasma sodium (F1,8 = 1.073, P = 0.331), plasma potassium (F1,8 = 3.087, P = 0.117), or
plasma chloride (F1,8 = 0.102, P = 0.758). Hemoglobin and hematocrit demonstrated no time x
trial interaction (Hemoglobin: F1,9 = 0.514, P = 0.494; Hematocrit F1,9 = 0.028, P = 0.872).
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Post-Exercise Urinalysis
Post-exercise, there was no difference between trials in the amount of fluid consumed
(ACT: 1007 ± 256 mL; PLA: 921 ± 448 mL, t10 = 0.874, P = 0.403). There was no difference in
spot sample USG assessed 3-h post trial between trials (t7 = -0.743, P = 0.487). Likewise, 3-h
spot sample urine osmolality was not different between trials (t7 = - 1.177, P = 0.287). Urgency
to void at 3-h post-trial was similar between trials (t7 = - 1.000, P = 0.351). Perception of thirst
was not different between trials at 3-h post-trial (t7 = - 0.3859, P = 0.711). Urine frequency posttrial to 3-h post-trial was not different between trials (t7 = - 1.528, P = 0.170). Post-exercise
urinalysis is presented in Table 3.
When individual samples over the 3-h post trial were combined and assessed in total for
USG, there were no differences between trials (t6 = - 1.774, P = 0.126). Combined urine
osmolality was not different between trials (t5 = - 0.614, P = 0.556). Total urine volume
immediately post-exercise to 3-h post-exercise was not different between trials (t7 = 1.090, P =
0.307) nor was there a difference between the percent of the bolus excreted by 3-h post trial (t9 =
0.648, P = 0.648).
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Table 1. Participant Descriptive Characteristics
n

Mass (kg)

11 58.7 ± 6.2

Height (cm)

Age (y)

VO2max (mL/kg/min)

Body Fat (%)

Relative Workload (W/kg)

163 ± 5

25 ± 6

47.8 ± 4.7

28.3 ± 5.8

1.8 ± 0.2

Note: Mean ± SD.
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Table 2. Blood Markers of Hydration Assessed Pre- and Post-Exercise by Trial Type
Active Trial
Placebo Trial
Measure
Pre-Exercise
Post-Exercise
Pre-Exercise
Post-Exercise
*
Plasma osmolality (mOsm/kg)
290 ± 4
293 ± 3
293 ± 4
294 ± 4*
Serum [Na+] (mEq/L)
141.0 ± 3.4
141.8 ± 3.9
141.2 ± 2.7
140.9 ± 2.6
+
#
Serum K , mEq/L
3.9 ± 0.4
4.4 ± 0.4
3.9 ± 0.2
4.2 ± 0.4#
Serum Cl-, mEq/L
104.8 ± 3.4
104.5 ± 3.9
105.0 ± 2.1
104.4 ± 2.6
13.2 ± 0.7
13.4 ± 0.5
13.3 ± 0.7
13.2 ± 0.8
Hemoglobin (g·dL-1)
Hct, %
41.5 ± 2.9
41.6 ± 1.6
41.3 ± 2.1
41.7 ± 2.6
Plasma volume change (%)
-5.4 ± 1.5
-4.9 ± 2.5
+
Note: Uosm=urine osmolality; USG=urine specific gravity; Sosm=serum osmolality; Serum [Na ] =serum sodium; Hb=hemoglobin;
Hct=hematocrit. *Significantly different from ACT trial, P = 0.036. #Significantly different from pre-trial, P < .001. Mean ± SD.

Table 3. Urinalysis and Perceptual Responses Assessed 3-h Post-Exercise
Measure
Active
Placebo
3-h spot USG
1.012 ± .008
1.014 ± .005
3-h spot Uosm (mOsm/kg)
437 ± 289
553 ± 161
Urgency
2±1
2±1
Thirst
5±2
5±2
Frequency
3±1
2±1
Total USG
1.009 ± .003
1.013 ± .007
Total Uosm, mOsm/kg
307 ± 121
381 ± 289
Total urine volume (mL)
465 ± 200
363 ± 260
Percent of bolus excreted (%)
50.6 ± 24.8
46.1 ± 30.0
Note: Uosm=urine osmolality; USG=urine specific gravity. Mean ± SD.
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Figure Legends
Figure 1. A) Rectal temperature during exercise in the heat comparing active and placebo phase
of OCP use. There was a significant main effect difference between trials (P < 0.001) and over
time (P < 0.001). There was not a time x trial interaction (P = 0.189). All time points were
significantly less than subsequent time points, regardless of trial (P ≤ 0.013). B) Demonstrates
skin temperature changes throughout trials. Regardless of trial, Tsk significantly increased over
time (F6,24 = 2.595, P=0.044) but there was no difference between trials (F1,4 = .902, P = 0.396).
There was no interaction effect for time x trial for Tsk(F6,24 = 0.856, P = 0.540). aIndicates
baseline Tsk was significantly lower than all other time points (P ≤ 0.002). Pairwise analysis
showed no other time point differences in Tsk. Error bars represent SD.
Figure 2. Demonstrates total sweat losses throughout trials. Total sweat loss was not different
between trials (P = 0.066). Lines within bars represent the mean whereas length of bars represent
SD. Individual responses are represented by connect dots.
Figure 3. Cardiovascular responses during exercise in the heat comparing active and placebo
phase of OCP use. A) There was a significant main effect for HR to increase over time regardless
of trial (P < 0.001). There was no difference between trials (P = 0.176). There was not a time x
trial interaction (P = 0.254). aIndicates a different heart rate than all other time points (P < .001).
b
Indicates a lower heart rate compared to 75 minutes and 90 minutes (P ≤ .002). cIndicates a
lower heart rate compared to 90 minutes (P = 0.033). B.) There was a significant main effect for
MAP to increase over time, regardless of trial (P = 0.015). There was no difference between
trials in MAP (P = 0.432) and there was not a time x trial interaction (P = 0.605). aIndicates a
significantly different MAP compared to 60-minute time points (P = 0.007). Error bars represent
SD.
Figure 4. Perceptual responses during exercise in the heat comparing active and placebo phase
of OCP use. A) RPE demonstrated a main effect for increasing over time regardless of trial (P <
0.001) with all-time points significantly less than subsequent time points (P ≤ 0.005). There was
a significantly greater RPE during the ACT trial (P = 0.007). There was not a time x trial
interaction for RPE. Pairwise comparisons demonstrated no difference between trials at each
time point (P ≥ 0.232). B) Thermal sensation increased, over time regardless of trial (P < 0.001).
There was no significant difference between ACT and PLA trials (P = 0.430) nor was there a
time x trial interaction (P = 0.694) for thermal sensation. aIndicates a significant lower thermal
sensation than all other time points (P ≤ .027). bIndicates a significantly lower thermal sensation
than 60- 75- and 90-minutes (P ≤ .043). cIndicates a significant difference from 75 and 90
minutes (P ≤ .034). C) Thirst sensation demonstrated a significant main effect for increasing over
time regardless of trial (P < 0.001). There was no significant difference between ACT and PLA
trials trial (P = 0.202) nor was there a time x trial interaction (P = 0.169). aIndicates significantly
lower perceived level of thirst when compared to all subsequent timepoints (P ≤ 0.002).
b
Indicates significant lower perceived level of thirst when compared to 45-, 75-, and 90-minute
timepoints (P ≤ 0.025). cIndicates significantly lower perceived thirst when compared to 45- and
90- minutes (P ≤ 0.012). dIndicates a significantly lower perceived level of thirst when compared
to 90-minutes (P ≤ 0.012). D) Perceived pain. Perceived pain demonstrated a main effect for
increasing over time regardless of trial (P < 0.001). There was no significant difference between
40

ACT and PLA trials trial (P = 0.170) nor was there time x trial interaction (P = 0.581). aIndicates
significantly lower perceived pain when compared to 60- and 75 minutes time points (P ≤
0.049). Error bars represent SD.
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V. Discussion
The purpose of this investigation was to evaluate the effects of combined (estradiol and
progestin) monophasic oral contraceptive pill (OCP) use on thermoregulation. We removed the
impact of dehydration by replacing 50% of sweat loss throughout exercise. We found that Tre
was significantly elevated during the ACT trial (third week of active pill dose). Other than a
greater baseline temperature, there were no thermoregulatory differences between trials and Tre
increases were not different between trials. Further, we sought to evaluate the effects of
combined monophasic OCP use on acute rehydration post-exercise in the heat according
recommended guidelines. We found no differences in fluid retention, thirst or fluid turnover
between trials.
Thermoregulation
As hypothesized, participants maintained a higher core temperature during exercise in the
heat when during ACT compared to PLA. Interestingly, there were no differences in Tsk or sweat
loss between trials. Overall, we demonstrated that the ACT phase of OCP use caused a greater
core temperature without a change to other thermoregulation variables. The change in Tre is
likely due to the previously identified hypothalamic “set-point” shift (Charkoudian & Johnson,
1997; Charkoudian & Stachenfeld, 2016; Rogers & Baker, 1996; Stachenfeld et al., 2000).
The preoptic region of the anterior hypothalamus (POAH) is primarily responsible for
body temperature control. Animal studies show that estrogen and progesterone act on sex steroid
binding neurons in the POAH and that estrogen appears to augment heat dissipation responses
(Silva & Boulant, 1986). The effect of progesterone on the hypothalamus is less clear
(Charkoudian & Stachenfeld, 2016). In humans, female reproductive hormones change the
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threshold temperature at which thermoregulatory responses (sweating and peripheral blood flow)
begin.
Previous research has shown during the luteal phase of eumenorrheic women, when
progesterone concentration is greatest, resting core body temperature is increased by 0.2-0.8°C
when compared to the early follicular phase (Baker et al., 2020; Charkoudian & Johnson, 1999;
Charkoudian & Stachenfeld, 2016; Constantini et al., 2005; Kolka & Stephenson, 1989; Pivarnik
et al., n.d.; Rogers & Baker, 1996; Tenaglia et al., 1999). The increased Tre is likely due to the
increased progesterone concentrations although estrogen is concomitantly increased
(Charkoudian & Johnson, 1997; Rogers & Baker, 1996; Tenaglia et al., 1999). The set-point shift
refers to the control of thermoregulatory physiology (onset of sweat) that is shifted to a higher
resting core temperature during the luteal phase. This hypothalamic adjusted set-point is not
unlike a fever, although mechanisms of action differ (Charkoudian & Stachenfeld, 2016). This
thermoregulatory set-point shift is maintained with OCP use and is further exacerbated with
exercise in hot and humid climates when thermoregulatory facilitation cannot compensate for
heat gain (T. Lei et al., 2019b). Some research has suggested that the greater resting core
temperature seen during ACT pill dosing is due to the residual effects of the menstrual cycle
(Tenaglia et al., 1999). However, it is plausible that the exogenous progesterones are responsible
for the set-point shift in OCP users (Charkoudian & Johnson, 1999; Charkoudian & Stachenfeld,
2016, 2014). Our data suggest that although both exogenous hormones are elevated during the
third week of ACT pill dosing that the effects of progestins are stronger than those of estrogen.
Human thermoregulation can simply be explained via the heat balance equation; S = W ±
C ± K ± R -E. Whereas, ‘S’ represents heat storage, and ‘W’ represents heat produced via
metabolic work. ‘C’ represents of a gain or loss of heat via convection (such as wind or fan use).
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‘K’ represents heat loss or gain via conduction to surfaces that have direct contact with the skin.
‘R’ represents heat loss or gain via radiation (such as the sun). ‘E’ represents heat loss via
evaporation. Evaporation is the primary driver of cooling and is responsible for 80-90% of heat
loss by sweat. In a hot and humid environment, heat loss is decreased due to the impairment of
sweat to evaporate from the skin. In an effort to dissipate heat, blood flow is directed to the
periphery decreasing blood flow to the working muscles, which is detrimental to performance.
Laboratory investigations of OCP use and thermoregulation have reported conflicting
evidence. Tenaglia et al, using similar phases as our study found that there was an elevated core
temperature during ACT but that the differences compared to PLA were less pronounced after 75
minutes of exercise in a hot and humid climate (40ºC and 30% RH). Baseline Tre was 0.22 ºC
greater during ACT, whereas our study had a similar 0.20 ºC increase during ACT. Also like our
study, there were no differences in sweat loss or sweat rate and there were no differences in the ∆
Tre between

phases (Tenaglia et al., 1999). However, their study focused on light intensity

exercise for long durations designed with intermittent bouts of treadmill walking between rest
intervals to determine heat tolerance. Lei et al. demonstrated a higher core resting temperature
during the quasi-mid-late luteal phase (days 10-20 of OCP use) that persisted through the first
stage of exercise (12 minutes) at a fixed work rate of 125W (T. Lei et al., 2019b). Interestingly,
the comparison of phases included a quasi-mid-late follicular (days 3-5 of OCP use) so that the
higher core temperature was significant compared to the first week of ACT rather than PLA. In
agreement with our findings, there was no difference in Tsk, although this comparison is not ideal
when using different days of OCP use in testing. To our knowledge, our study is the first to
demonstrate an elevated core temperature throughout 90 minutes of moderate-vigorous aerobic
exercise.
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In our study, we aimed to control variables in the heat balance equation to isolate effects
of OCP phase on heat storage. Metabolic work was controlled and there were no differences
between trials in heat production (ACT: 9.37 ± 0.8 W/kg; PLA: 9.29 ± 0.74 W/kg). A fan was
used during trials but was matched between trials. This allowed a control for convection.
Radiation and conduction were not quantified but all trials were conducted under the same
conditions within our environmental chamber. Further, there were no differences in sweat loss
between trials. Controlling for all other variables within the heat balance equation suggests that
the defining outcome of our study was heat storage compared between trials. Tre was
significantly greater during active pill dosing. Further, there was no differences in ∆Tre (ACT:
1.3 vs. PLA: 1.4 ºC), reaffirming the previously defined set point shift due to greater
concentrations of progestins.
It should be noted that we compared the third week of active pill dosing when exogenous
hormone concentration is highest. This does not account for the first two weeks of pill use and,
therefore limits our findings to application across a month of OCP use. We maintained an
acceptable level of dehydration (< 2%) throughout trials; therefore, we cannot ascertain any
exacerbating effects of combined dehydration and exercise in the heat with OCP use. It should
also be considered that VO2peak tests were not all taken during the same OCP dosing phase.
While we do not believe this would have changed our outcomes, there is a possibility that power
output would have varied due to RPE, and work rate would have been established at a different
% of VO2. We used 55% of peak wattage achieved during our VO2peak tests to determine
workload. This method caused a greater percentage of max VO2 to be achieved during trials. On
average, our participants cycled at 68% ± 6% of VO2peak however, this is intensity is quite
applicable to trained individuals. Unfortunately, our intent to randomize trials was inhibited by
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the feasibility of our timeline. Ten out of 11 participants completed the ACT trial first. Trials
were separated by at least 7 days and conducted from November-March when the potential for
acclimation is not likely.
Thermoregulation conclusions
Our results confirm previously reported increases of core temperature during ACT dosing
of OCP use during exercise in the heat. We also demonstrated a greater RPE during ACT. We
did not find any other differences between pill phases in measured thermoregulatory variables.
Considering these results, we do not believe that exercising during ACT increases risk during
exercise in the heat, but it may be pertinent for some individuals to note especially when
performance outcomes are prioritized. One of our participants reached 40.08ºC during ACT in
comparison to 39.77 ºC during PLA. Our study provided a fixed work intensity causing Tre to
continually rise. It is possible that an attenuation in performance would be observed in self-paced
exercise to avoid greater core temperatures (Lee et al., 2010). Contrarily, if work rate was held
constant, this individual could be at risk for heat injury.
In some military settings, heat intolerance is defined as a peak Tre of 38.5 °C, a peak HR
< 150bpm or the inability to reach equilibrium at these values. Using this criterion, 67% of
female participants are classified as “heat intolerant” compared to 33% of males (Druyan et al.,
2012). As demonstrated in our study, females got significantly hotter during the ACT pill dosing
although they did not exhibit symptoms of heat stress. While recognizing that this is a drastically
different protocol, it may be beneficial that heat tolerance tests consider the variability of core
temperature based on OCP phase.
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Perceptual Measures
Participants reported a greater rating of perceived exertion (RPE) during the ACT pill
dosing but there no differences in perceived thirst, perceived pain, or thermal sensation between
trials. To our knowledge, there are no previous studies comparing perceptual data in
OCP users. Therefore, we can only compare our findings to those in eumenorrheic females. For
the purpose of comparison, we can assume that the greater hormone concentration in ACT is
similar to that of the luteal phase. Janse De Jonge et al. (2012) investigated exercise performance
over the menstrual cycle in a hot and humid environment and similar to our study found that
participants reported a greater RPE during the luteal phase when compared to the early-follicular
phase. Like our study, participants did not report a difference in thermal sensation between trials.
Lei et al. (2017) investigated perceptual measures during different phases of the menstrual cycle
in eumenorrheic females during self-paced exercise and found no differences in thermal or thirst
sensation or RPE between phases of the menstrual cycle (T.-H. Lei et al., 2017). These findings
are in agreement with Sunderland and Nevill (2003) whose participants also did not report
differences in RPE between menstrual cycle phase while intermittently running in the heat.
However, our data suggest that RPE is greater during the ACT phase of OCP use. Therefore,
there may be practical recommendations for endurance athletes to align competition or training
with pill dosing phase especially in hot, humid conditions as training and performance responses
may be dependent on RPE (Janse De Jonge et al., 2012; Sunderland & Nevill, 2003).
Post-Exercise Fluid Balance
As hypothesized, there was no difference in fluid retention or fluid turnover postexercise. This study used a bout of exercise in the heat (total ~90 minutes) to assess
thermoregulatory variables. To make conclusions regarding thermoregulation, by design,

51

participants were prevented from becoming dehydrated (no more than 2% body mass loss) to
avoid a combination of heat stress and hypohydration. Therefore, by using recommended sport
guidelines for rehydration, the study provided an opportunity to assess fluid balance in OCP
users post-exercise in the heat without concomitant effects of dehydration.
Sex differences in fluid balance, for instance sweating rates, are considered in hydration
recommendations but do not address menstrual cycle phase or OCP use. Greater variability may
exist within phases of the menstrual cycle verses differences between sex (Sims & Heather,
2018). Arginine vasopressin (AVP) has a lower osmotic threshold for stimulation when estrogen
concentration is greater. Further, both endogenous and exogenous estrogens and progesterones
promote water and sodium retention (Sims et al., 2008b; Stachenfeld & Keefe, 2002; Stachenfeld
& Taylor, 2005b). However, our study did not find differences between phases of OCP use.
To our knowledge, this study is the first to investigate acute rehydration post-exercise in
OCP users. Rodriguez-Guistiniani and Galloway previously investigated rehydration in
eumenorrheic females and similarly dichotomized hormone profiles (mid luteal and early
follicular) (Rodriguez-Giustiniani & Galloway, 2019). They reported no significant differences
between menstrual cycle phase in urine volume or percent fluid retained after females were
dehydrated to 2% body mass via fluid restriction and exercise in the heat. Their rehydration
protocol included an amount of 100% body mass loss consumed in 4 equal boluses over thirty
minutes. While their study consisted of eumenorrheic women and ours OCP users, both
compared two different phases of greater and lesser hormone concentration. Neither their study
nor ours identified differences in fluid balance post-exercise in the heat. In investigating
eumenorrheic females vs. OCP users, it should be noted that the hormone profiles are not easily
compared. OCP use turns off hypothalamic-pituitary-gonadal axis and provides an greater
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concentration of exogenous hormones (Sims & Heather, 2018). However, previous research in
our lab investigated the differences in OCP use in euhydrated, resting conditions. We found no
differences in percent bolus excreted or volume turnover between OCP phases. Our study
prevented participants from becoming dehydrated even when undergoing exercise in the heat.
Our findings suggest that, in euhydrated scenarios, fluid balance may be tightly regulated to
prevent influence of sex hormones.
Maintaining euhydration during exercise is difficult, especially when environmental
conditions promote heavy sweating (i.e., in hot and humid conditions). Suboptimal hydration
status may have implications to safety and performance. More so, poor hydration may also
hinder recovery following exercise in the heat. Therefore, rehydration strategies have been
recommended for physically active individuals (McDermott et al., 2017; Sawka, 2007). Those
strategies include preventing dehydration greater than 2% of body mass loss during exercise
(although detriments as small as 1% can affect performance) and replenishing fluid loss postexercise. It is recommended that 125-150% of body weight loss should be consumed within 4-h
post-exercise in recovery food and fluid (McDermott et al., 2017; Sawka et al., 2007, Sherriffs,
2004). We chose to provide recovery fluids equal to 125% body weight loss. This amount would
be reasonable to achieve and applicable in a real-world scenario. Knowing that the exact amount
of fluid needed to restore euhydration would depend on macronutrient content, we chose to
provide a recovery beverage (P:26 g/CHO:6 g/F: 4.5 g) as well as water to facilitate appropriate
rehydration. The additional consumption of electrolytes (sodium) and carbohydrates ideally
compensated for the post-exercise diuresis and was matched between trials (McDermott et al.,
2017).
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As this study was part of a larger investigation of thermoregulation, there were
limitations to this methodology. We provided participants with rehydration beverages to finish
within one hour of completing exercise. Participants finished recovery fluids before leaving the
laboratory, therefore, we relied on participants to complete the procedure and verbally confirm
compliance at urine drop-off. The goal of this study was to assess differences in fluid handling
post-exercise in the heat. Several analyses may be underpowered, increasing our risk of a Type 1
error. This is due to our small sample size and the use of paired samples t-tests. However,
previous research in our lab (with a larger sample size) showed no differences in OCP phase
when participants were euhydrated in resting conditions. Considering the design of the current
study in that participants finished no greater than 2% dehydrated we believe that it would be
unlikely to find significant differences due to tightly regulated physiological fluid volume
control.
Fluid Balance Conclusions
In conclusion, the findings of this study apply to females who use OCPs and exercise or
work in hot and humid environments. We demonstrate no significant impact of OCP phase to
post-exercise fluid balance. These findings pertain to a maintenance of euhydration during
exercise and proper recovery based on previously published guidelines for physically active
individuals. Specifically, when maintaining no greater than 2% body mass loss during exercise
and meeting proper recovery suggestions of 125% body mass loss in replenishing fluid is met.
Although not the goal of our study, our rehydration protocol of 125% replacement ensured that
participants maintained euhydration for 3-h post-trial, confirmed by a 3-h total USG of 1.012 ±
0.007 and a 3-h-spot USG of 1.013 ± 0.006 . If participants finished exercise hypohydrated, or
failed to recover properly, there may have been differences in fluid handling due to estrogens
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affinity with AVP (Stachenfeld, 2008; Stachenfeld & Keefe, 2002). However, we see no need for
OCP users to follow rehydration guidelines other than those currently recommended. As such, to
improve best outcomes, recovery fluids and prevention of exercise dehydration is necessary.
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